SmartHealth Ecosystem Event 12.6.2019, Tatu Laurila presentation on How to make best out of Finnish health data for future global innovation and precision medicine?

1. PreMed – how to make best out of Finnish
health data for future global innovation and
precision medicine?
Tatu Laurila, Head Market Access, Novartis Finland
Novartis Finland

2. Novartis Finland
| Novartis Finland2
From a chemical company to a leading
medicines company

3. Novartis Finland
Focusing Novartis as a leading medicines
company powered by data and digital
| Novartis Finland3
Science
TechnologyData
Unleashthe power of our
people
Delivertransformative
innovation
Embraceoperational
excellenceeveryday
Go big on data and digital Return moreto society

4. Novartis Finland
+2 million patient years of clinical trial
data
| Novartis Finland4

5. Novartis Finland
Managing +500 clinical trials via one
central control center
| Novartis Finland5

6. Novartis Finland
Bringing the trial to the patient
6
Conventional model: Site Centric Disruptive trial model: Patient Centric
Nearby medical
committee
Virtual PI
Remote nurse
visits
Mobile Health
Devices
Sponsor EDC
Database
Patient
Only 3% of adult
cancer patients of
the U.S participate
in clinical trials*
3%
~20% of sites
enroll no patients
in their studies*
20%
30% of patients
drop out of a
clinical trial*
30%
Only 20% of
clinical trials
finish on time*
20%
| Novartis Finland *https://www.ciscrp.org/education-center/charts-and-statistics/before-participation/
Example of partner:

7. Novartis Finland
Building foundations at scale Driving medical innovation Next generation commercial
Working with external partners to
accelerate our transformation
| Novartis Finland7

8. Novartis Finland
 Finnish Business Delegation in Basel HQ Sep
2018
 Theme: Go Big in Data and Digital
 30+ Finnish companies
 Minister Saarikko and key public stakeholders
 Health and innovation policy discussions with NVS
senior management
 1on1 discussions between companies and NVS
leaders
| Novartis Finland8
Finland example: start-up aiming
global with Novartis and beyond
Novartis
Chairman Dr.
Jörg Reinhardt
in Go Big in
Data & Digital
meeting

9. VTT’s PreMed project
Promote development of a data-driven precision medicine ecosystem in Finland
Novartis Finland

10. Novartis Finland
PreMed partners represent health
ecosystem broadly
Avaintec Oy, https://www.avaintec.com
Biopankkien Osuuskunta Suomi - FINBB, https://finbb.fi
Crown CRO Oy, http://crowncro.fi
Oy Karl Fazer Ab, https://www.fazer.fi
Medaffcon Oy, https://www.medaffcon.fi
Mediconsult Oy, https://www.mediconsult.fi
Novartis Finland Oy, https://www.novartis.fi
Pfizer Oy, https://www.pfizer.fi
Roche Diagnostics Oy, https://www.roche.fi/
VTT Technical Research Centre of Finland, https://www.vtt.fi
The project is led and and performed by VTT Technical Research Centre of Finland (Teknologian tutkimuskeskus VTT Oy). The biobank study
execution is supported by Medaffcon Oy and external clinical advisors. All partners contribute to the project through participation in the project
steering group. The project is jointly financed by Business Finland and the project partners. Continuation: Q2 2017- Q2 2020
| Novartis Finland10
Fazer

11. Novartis Finland
PreMed objectives
1. Collect and disseminate information of on-going national and international
activities
2. Assess precision medicine ecosystem needs and bottlenecks
3. Identify new business strategies and models
4. Provide recommendations to public bodies
5. Carrying out a biobank study to assess data exploitation opportunity and
clinical relevance in a selected application area (pharmacogenomics of
antithrombotic drugs)
| Novartis Finland11

12. Novartis Finland
| Novartis Finland12

13. Novartis Finland
Novartis expectations to PreMed
project
 Test and demonstrate Finland capacities, competences and capabilities in data
driven precision medicine
 Accelerate secondary use of health data in Finland to fulfill Novartis’ global
needs
 Enhance Novartis future investments into Finland based on win-win value
propositions
 Grow Novartis footprint in Finland and Finland footprint at Novartis
 Make sure that Finnish patients will benefit from newest precision medicines
from early development phases onwards
| Novartis Finland13

14. Thank you